New ways to prevent urinary tract infections
Investigating Novel Methods to Combat Urinary Tract Infections
This study is looking for new ways to treat urinary tract infections caused by tough bacteria, and it’s for anyone who has struggled with these infections; researchers are testing a special antibody that might stop the bacteria from sticking to the urinary tract, helping to create better treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10705027 on NIH RePORTER |
What this research studies
This research focuses on developing innovative treatments for urinary tract infections (UTIs), particularly those caused by drug-resistant bacteria like Klebsiella pneumoniae. The approach involves creating anti-adhesive molecules that prevent bacteria from attaching to the cells in the urinary tract, which is a critical step in infection. The study will explore the mechanism of action of a specific monoclonal antibody that has shown promise in blocking bacterial adhesion. By understanding how this antibody works, researchers aim to design new therapies that can effectively combat UTIs.
Who could benefit from this research
Good fit: Ideal candidates for this research include children, the elderly, diabetics, and immunocompromised individuals who are at higher risk for recurrent urinary tract infections.
Not a fit: Patients who do not suffer from urinary tract infections or those with infections caused by non-target bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the incidence and severity of urinary tract infections, especially in patients with limited treatment options.
How similar studies have performed: Previous research has shown promise in using monoclonal antibodies to inhibit bacterial adhesion, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Magala, Pearl — University of Washington
- Study coordinator: Magala, Pearl
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.